Active, not recruitingPHASE1, PHASE2NCT03784066

Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity

Studying Squamous cell carcinoma of the oral cavity

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Universitaire Ziekenhuizen KU Leuven
Principal Investigator
Paul Clement, Prof.
UZ Leuven
Intervention
Durvalumab(drug)
Enrollment
21 target
Eligibility
18 years · All sexes
Timeline
20182026

Study locations (1)

Collaborators

AstraZeneca · European Organisation for Research and Treatment of Cancer - EORTC · Vlaams Instituut voor Biotechnologie (VIB)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03784066 on ClinicalTrials.gov

Other trials for Squamous cell carcinoma of the oral cavity

Additional recruiting or active studies for the same condition.

See all trials for Squamous cell carcinoma of the oral cavity

← Back to all trials